Zhejiang Hisun Biomaterials Co (SHSE:688203) EBIT: ¥24.6 Mil (TTM As of Mar. 2026)


SHSE:688203 Zhejiang Hisun Biomaterials Co Ltd SHSE:688203
77 GF Score
Price ¥10.00
GF Value ¥13.89
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Zhejiang Hisun Biomaterials Co EBIT?

Zhejiang Hisun Biomaterials Co SHSE:688203 -0.79% 77 EBIT is ¥24.6 Mil as of Mar. 2026. GuruFocus rates SHSE:688203 with a GF Score™ of 77/100 and a GF Value™ of ¥13.89 (Modestly Undervalued). The stock has 8 warning signs investors should review.

Zhejiang Hisun Biomaterials Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥4.8 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥24.6 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Zhejiang Hisun Biomaterials Co's annualized ROC % for the quarter that ended in Mar. 2026 was 0.52%. Zhejiang Hisun Biomaterials Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 1.52%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Zhejiang Hisun Biomaterials Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 1.23%.


Zhejiang Hisun Biomaterials Co  (SHSE:688203) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Zhejiang Hisun Biomaterials Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=28.204 * ( 1 - 71.4% )/( (1565.011 + 1552.24)/ 2 )
=8.066344/1558.6255
=0.52 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2047.524 - 281.388 - ( 328.295 - max(0, 500.125 - 701.25+328.295))
=1565.011

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2019.456 - 262.662 - ( 261.48 - max(0, 474.716 - 679.27+261.48))
=1552.24

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Zhejiang Hisun Biomaterials Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=19/( ( (1209.704 + max(18.558, 0)) + (1205.338 + max(65.826, 0)) )/ 2 )
=19/( ( 1228.262 + 1271.164 )/ 2 )
=19/1249.713
=1.52 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(47.215 + 192.485 + 87.281) - (281.388 + 0 + 27.035)
=18.558

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(86.757 + 194.617 + 78.86) - (262.662 + 0 + 31.746)
=65.826

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Zhejiang Hisun Biomaterials Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=24.588/1993.314
=1.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhejiang Hisun Biomaterials Co EBIT Related Terms


Zhejiang Hisun Biomaterials Co EBIT Historical Data

* Premium members only.

The historical data trend for Zhejiang Hisun Biomaterials Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Hisun Biomaterials Co EBIT Chart

Zhejiang Hisun Biomaterials Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial 49.10 62.21 60.78 54.78 23.72

Zhejiang Hisun Biomaterials Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.88 8.69 6.47 4.68 4.75

SHSE:688203 vs DOW: EBIT Comparison

For the Chemicals subindustry, Zhejiang Hisun Biomaterials Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Hisun Biomaterials Co EV-to-EBIT vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, Zhejiang Hisun Biomaterials Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Zhejiang Hisun Biomaterials Co's EV-to-EBIT falls into.


SHSE:688203
77GF Score
Zhejiang Hisun Biomaterials Co Ltd SHSE:688203
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhejiang Hisun Biomaterials Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥24.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥24.6 Mil mean?
Zhejiang Hisun Biomaterials Co (SHSE:688203) has a EBIT of ¥24.6 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Zhejiang Hisun Biomaterials Co.
Is Zhejiang Hisun Biomaterials Co's EBIT too high?
Zhejiang Hisun Biomaterials Co's current EBIT is ¥24.6 Mil. Overall, Zhejiang Hisun Biomaterials Co has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Hisun Biomaterials Co's EBIT compare to DOW?
Zhejiang Hisun Biomaterials Co's EBIT of ¥24.6 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Chemicals company?
A good EBIT depends on the Chemicals industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Zhejiang Hisun Biomaterials Co. Zhejiang Hisun Biomaterials Co's current EBIT is ¥24.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Hisun Biomaterials Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Hisun Biomaterials Co (SHSE:688203) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥13.89, compared to a current price of ¥10.00 — trading 28% below its estimated fair value. The current EBIT is ¥24.6 Mil. Zhejiang Hisun Biomaterials Co's overall GF Score™ is 77/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Zhejiang Hisun Biomaterials Co (SHSE:688203), the current EBIT is ¥24.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang Hisun Biomaterials Co (SHSE:688203) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Hisun Biomaterials Co stock appears to be undervalued. The current stock price of ¥10.00 is trading 28% below its estimated GF Value™ of ¥13.89. GuruFocus considers Zhejiang Hisun Biomaterials Co to be Modestly Undervalued.

Key valuation signals for SHSE:688203:

  • EBIT: ¥24.6 Mil
  • GF Value™: ¥13.89 vs. price of ¥10.00 (28% below fair value)
  • GF Score™: 77/100 with 8 warning signs

No single metric tells the full story. See the SHSE:688203 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zhejiang Hisun Biomaterials Co Business Description

Address No. 293 Gongong Road, Room 301-07, Jiaojiang District, Zhejiang Province, Taizhou, CHN, 318000
Zhejiang Hisun Biomaterials Co Ltd is engaged in the research and development, production and sales of polylactic acid.
77GF Score

Get the complete analysis for SHSE:688203

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥10.00
Price
¥13.89
GF Value